🧾 What This Document Is — And Why You Got It

This is MannKind's definitive proxy statement (DEF 14A). Think of it as the official "meeting agenda" and information packet for shareholders ahead of the annual meeting. Its main jobs are to give you the details you need to vote on company business and to explain how the company is run, including how much the bosses get paid.

👉 In short: This document tells you what's being voted on, who's running the company, and how they are compensated. You received it because you own shares.

🏢 What MannKind Does

MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. They don't just make drugs; they specialize in drug-device combination products, often using their proprietary dry-powder inhaler technology.

👉 Their key products & pipeline:

• Afrezza: An inhaled insulin for diabetes.
• Furoscix: An injectable diuretic (acquired in Oct 2025).
• V-Go: A wearable insulin delivery device.
• Tyvaso DPI (with partner United Therapeutics): An inhaled powder for pulmonary hypertension.
• Pipeline: They have other inhaled therapies in development, like MNKD-201 for idiopathic pulmonary fibrosis (IPF).

📅 The 2026 Annual Meeting Details

• When: Wednesday, May 20, 2026, at 9:00 a.m. ET.
• Where: Virtual only. You can attend and vote online at: www.virtualshareholdermeeting.com/MNKD2026.
• Record Date: March 23, 2026. Only shareholders on this date can vote.
• Quorum Needed: At least 154,397,889 shares must be present (that's a majority of the ~308.8 million outstanding).

👉 Why a virtual meeting? MannKind says it saves money and allows more shareholders, regardless of location, to attend and participate equally.

🗳️ What You're Voting On (The 3 Proposals)

The Board recommends a "FOR" vote on all three proposals.

Proposal 1: Elect 9 Directors

You're voting on nine people to run the company for the next year. The nominees are a mix of company founders, medical experts, and business veterans. Key names include:

• Dr. Michael Castagna (CEO)
• Dr. Alfred Mann (Founder & former CEO)
• Steven Binder (Lead Independent Director)

👉 Why it matters: The board sets the company's strategy and oversees management. Your vote chooses who sits at that table.

Proposal 2: Advisory Vote on Executive Pay ("Say-on-Pay")

This is your chance to give a non-binding "thumbs up" or "thumbs down" on how much the top executives were paid in 2025.

👉 Why it matters: Even though it's not binding, a strong "FOR" vote signals shareholder approval of the compensation philosophy. The company notes it received 91% support on this vote in 2025.

Proposal 3: Ratify the Auditor

You're being asked to approve the selection of Deloitte & Touche LLP as the company's independent auditor for 2026. Deloitte has been the auditor since 2001.

👉 Why it matters: This is a routine but important check on financial oversight. The total audit fees for 2025 were $1,696,228.

👥 Who's Running the Show: Board & Leadership

The board is proposed to have 9 members, with specialized committees (Audit, Compensation, Nominating). Here’s a snapshot of the executive team:

• CEO: Michael Castagna, Pharm.D.
• CFO: Christopher Prentiss
• Chief Medical Officer: Ajay Ahuja, M.D., MBA (new as of Sept 2025)
• President, Endocrine Business: Dominic Marasco (new as of Jan 2025)

💼 How Executives Get Paid: The Philosophy

MannKind's compensation plan is built on a pay-for-performance model.

👉 Key principles:

• A large portion of pay is "at risk," tied to hitting company goals.
• Equity (stock) awards are used heavily to align executives with shareholders.
• They target total pay around the median of their 13-company biotech peer group (like ADMA Biologics, Insmed, etc.).
• No guaranteed bonuses or tax gross-ups.
• They have a "clawback" policy to recover pay if financials are restated.

For 2025, about 69% of the CEO's total compensation was performance-based.

⚖️ Governance & Policies

The company outlines several policies designed to ensure good behavior:

• Related-Person Transactions: A strict policy to review any deals with insiders. No such transactions were reported in 2025.
• Insider Trading & Hedging: Employees and directors are prohibited from short selling, trading on margin, or hedging company stock.
• Stock Ownership Guidelines: Directors and executives are required to hold a significant amount of company stock to ensure their interests are aligned with yours.

🔮 What's Next & Strategic Direction

Beyond the meeting, the company is focused on:

• Growing its cardiometabolic portfolio with Afrezza, Furoscix, and V-Go.
• Advancing its orphan lung disease pipeline, especially MNKD-201 (for IPF) in Phase 2 trials.
• Expanding its partnership with United Therapeutics to develop new therapies like MNKD-1501.

🧠 The Analogy

Think of this proxy statement like a package insert for a board game called "MannKind Corporation." The "rules" (governance policies) explain how to play fairly. The "player cards" (director bios) tell you who the key characters are and their special skills. The "reward system" (executive compensation) explains how the players score points. And the "voting tokens" (your shares) let you decide which players get to stay on the board for the next round.

🧩 Final Takeaway

This is your annual review of MannKind's leadership and governance. The core ask is straightforward: renew the board, approve the pay plan, and keep the auditor. More deeply, the document reveals a company trying to balance growth in commercial products with high-risk pipeline development, using a compensation plan that heavily ties executive wealth to long-term company and stock performance.